Equities Analysts Offer Predictions for IRWD Q3 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research raised their Q3 2025 EPS estimates for shares of Ironwood Pharmaceuticals in a report released on Thursday, May 1st. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of $0.08 for the quarter, up from their prior forecast of $0.06. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million.

A number of other equities analysts have also weighed in on the stock. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 16th. Jefferies Financial Group restated a “hold” rating and issued a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. StockNews.com cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 15th. Citizens Jmp lowered shares of Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 14th. Finally, Leerink Partners lowered their price target on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating on the stock in a research note on Monday, April 14th. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average price target of $4.78.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $0.93 on Friday. The company has a market capitalization of $150.85 million, a P/E ratio of -31.08 and a beta of 0.30. Ironwood Pharmaceuticals has a 52 week low of $0.59 and a 52 week high of $8.45. The company’s 50 day moving average price is $1.23 and its two-hundred day moving average price is $2.79.

Institutional Trading of Ironwood Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its position in Ironwood Pharmaceuticals by 4.0% during the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after acquiring an additional 450,949 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock valued at $8,786,000 after buying an additional 78,969 shares during the period. SG Americas Securities LLC acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter worth approximately $53,000. Amundi increased its stake in Ironwood Pharmaceuticals by 168.4% during the 4th quarter. Amundi now owns 61,979 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 38,889 shares during the period. Finally, Los Angeles Capital Management LLC raised its holdings in Ironwood Pharmaceuticals by 2,625.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 331,700 shares of the biotechnology company’s stock valued at $1,469,000 after acquiring an additional 319,528 shares in the last quarter.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 192,381 shares of company stock worth $338,591. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.